We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
151
DELISTED
Hologic
HOLX
$2.17M 0.08%
32,564
– –
RVNC
152
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.16M 0.08%
85,840
– –
OVID icon
153
Ovid Therapeutics
OVID
$474M
$2.14M 0.08%
372,733
– –
MEDP icon
154
Medpace
MEDP
$16.1B
$2.11M 0.08%
18,871
– –
ALC icon
155
Alcon
ALC
$34.6B
$2.09M 0.08%
36,686
– –
CLLS
156
Cellectis
CLLS
$279M
$2.04M 0.08%
110,147
– –
HRTX icon
157
Heron Therapeutics
HRTX
$96.8M
$1.94M 0.07%
131,183
– –
BHC icon
158
Bausch Health
BHC
$2.41B
$1.84M 0.07%
118,412
– –
HR icon
159
Healthcare Realty
HR
$7.02B
$1.84M 0.07%
70,662
– –
KURA icon
160
Kura Oncology
KURA
$841M
$1.82M 0.07%
+59,339
New +$1.31M
HARP
161
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.81M 0.07%
+10,642
New +$1.53M
ENDP
162
DELISTED
Endo International plc
ENDP
$1.75M 0.07%
531,570
– –
MDGL icon
163
Madrigal Pharmaceuticals
MDGL
$11.7B
$1.58M 0.06%
13,340
– –
MIST icon
164
Milestone Pharmaceuticals
MIST
$146M
$1.56M 0.06%
213,310
– –
ESPR
165
DELISTED
Esperion Therapeutics
ESPR
$1.54M 0.06%
41,577
– –
EXAS
166
DELISTED
Exact Sciences
EXAS
$1.54M 0.06%
15,150
-28,865
-66% -$2.49M
ADUS icon
167
Addus HomeCare
ADUS
$2.12B
$1.51M 0.06%
15,969
– –
INGN icon
168
Inogen
INGN
$187M
$1.49M 0.06%
51,406
– –
DNTH icon
169
Dianthus Therapeutics
DNTH
$6.04B
$1.31M 0.05%
12,027
– –
DHC
170
Diversified Healthcare Trust
DHC
$2.13B
$1.26M 0.05%
357,720
– –
NVAX icon
171
Novavax
NVAX
$1.26B
$1.25M 0.05%
11,523
-17,027
-60% -$2.07M
DRNA
172
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.23M 0.05%
+68,150
New +$1.41M
GSK icon
173
GSK
GSK
$103B
$1.22M 0.05%
25,920
-150,290
-85% -$7.53M
ADPT icon
174
Adaptive Biotechnologies
ADPT
$3.9B
$1.2M 0.05%
+24,715
New +$1.04M
AVDL
175
DELISTED
Avadel Pharmaceuticals
AVDL
$1.18M 0.04%
233,612
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.